Test Price
2,800 AED✅ Home Collection Available
MET Gene (Hereditary Papillary Renal Cell Carcinoma Type 1) Genetic Test in UAE
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
Clinical Guidance: Telephonic Pre- and Post-Test Genetic Counseling with a Consultant Medical Geneticist.
Insurance Support: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This next‑generation sequencing (NGS) test analyzes the entire coding region of the MET proto‑oncogene to identify germline mutations causing hereditary papillary renal cell carcinoma type 1 (HPRCC). For patients in the UAE, the test provides a definitive molecular diagnosis that guides lifelong renal surveillance and cascade family screening.
| Feature | Our Test (Precision Panel) | Closest Alternative |
|---|---|---|
| Method | NGS with full gene coverage & CNV detection | Single‑gene Sanger sequencing (limited sensitivity) |
| Analytical Sensitivity | 99.9% (detects SNVs & deletions) | ~95% (misses large rearrangements) |
| Turnaround Time | 3–4 Weeks | 4–6 Weeks |
| Pre‑test Genetic Counselling | Included (pedigree mapping session) | Often not provided |
Physician Insight & Safety Protocols
Medication & Clinical Safety Advisory
⚠ Important Safety Information
Do not discontinue prescribed medication without consulting your doctor. This genetic test is for risk assessment only and does not replace ongoing oncological care.
Exclusion Criteria: Individuals unable to provide informed consent; minors without court‑appointed guardian consent (per Federal Decree-Law No. 4 of 2016 on Medical Liability). Test not indicated for somatic tumor profiling.
Emergency Red Flags: Sudden flank pain, visible blood in urine, new palpable abdominal mass, or unexplained weight loss — seek immediate urology evaluation.
Patient FAQ & Clinical Guidance
1. What does the MET gene test detect?
Identifies genetic mutations in the MET gene responsible for inherited papillary renal cell carcinoma type 1. This test examines all coding exons of the MET gene to pinpoint hereditary variants that dramatically increase the lifetime risk of bilateral, multifocal kidney tumors. A positive result enables proactive imaging surveillance and early intervention.
2. Who should consider this test?
Individuals with a family history of early-onset kidney cancer or multiple family members with renal tumors. Any person with a first‑degree relative known to carry an MET mutation, or those with a personal/family history of papillary renal cell carcinoma diagnosed before age 45, should undergo genetic counseling and consider cascade testing.
3. How accurate is the NGS test?
NGS achieves >99.9% analytical sensitivity and specificity for detecting known MET gene variants. Our platform uses dual‑strand sequencing and advanced bioinformatics to minimize false positives, ensuring that a negative report truly rules out the targeted mutation. All results are confirmed by an ISO‑certified molecular genetics laboratory.
4. How is the sample collected?
A standard peripheral blood draw (EDTA whole blood) is required. Our VIP Mobile Phlebotomy service will visit your home or office between 8 AM and 11 PM daily, using temperature-controlled cold-chain transport to ensure sample integrity. Alternatively, you may visit our DHA-licensed facility in Dubai Healthcare City.
5. What is the turnaround time?
Results are typically available within 3–4 weeks. This time frame accounts for DNA extraction, library preparation, sequencing, bioinformatics analysis, and clinical interpretation. Urgent cases may be expedited upon request.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance Framework
This genetic test and its associated data handling strictly comply with:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – ensuring patient consent, data minimization, and secure processing of genetic information.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – governing electronic health records and telemedicine.
- Federal Decree-Law No. 4 of 2016 on Medical Liability – covering informed consent and clinical responsibility.
All genetic data is encrypted in transit and at rest, accessible only to authorized clinical personnel. Patients have the right to access, rectify, and request deletion of their data in accordance with PDPL.
Clinical & Logistical Metadata
| Test Name | MET Gene (Hereditary Papillary Renal Cell Carcinoma Type 1) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA) – VIP Mobile Phlebotomy Available |
| Methodology Used | Next-Generation Sequencing (NGS) with Full Gene Coverage & CNV Detection |
| ICD-10-CM Code | C64.9 (Malignant neoplasm of kidney, unspecified), Z80.5 (Family history of malignant neoplasm of urinary tract) |
| LOINC Code | 21626-7 (DNA analysis for hereditary disorder panel) |
| DHA Facility License & Laboratory Address | DHA License No: 1143 | DNA Labs UAE – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians